Cargando…
Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor
BACKGROUND AND AIMS: Refractory pruritus and other complications of cholestasis are indications for liver transplantation (LT) in patients with Alagille syndrome (ALGS). We evaluated predictors of event-free survival and transplant-free survival in patients with ALGS treated with maralixibat (MRX),...
Autores principales: | Sokol, Ronald J., Gonzales, Emmanuel M., Kamath, Binita M., Baker, Alastair, Vig, Pamela, Mogul, Douglas B., Garner, Will, Hansen, Bettina E., Jacquemin, Emmanuel, Thompson, Richard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653287/ https://www.ncbi.nlm.nih.gov/pubmed/37278241 http://dx.doi.org/10.1097/HEP.0000000000000502 |
Ejemplares similares
-
A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans
por: Caballero-Camino, Francisco J., et al.
Publicado: (2023) -
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
por: Hirschfield, Gideon M., et al.
Publicado: (2023) -
Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome
por: Shneider, Benjamin L., et al.
Publicado: (2022) -
Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Hoilat, Gilles Jadd, et al.
Publicado: (2021) -
Interventional treatment of biliodigestive anastomosis leaks with a modified percutaneous transhepatic cholangiodrainage
por: Lopez Benitez, Ruben, et al.
Publicado: (2022)